Investment Rating - The report assigns a "Buy" rating to AIA Group with a 12-month price target of HK$90, indicating an upside potential of 30.5% from the current price of HK$68.95 [11][12]. Core Insights - AIA Group is focused on share buybacks, with a decision to shorten the buyback period to three months to capitalize on low share prices. The next buyback decision is expected to align with FY25 results [5]. - The company anticipates limited impact from interest rate changes, with a positive translation effect from the weakness of the USD. The business in mainland China and Thailand is negatively affected by lower rates, while operations in Hong Kong, Singapore, and Malaysia benefit from them [5][10]. - AIA is actively expanding its footprint in mainland China, aiming to grow agent numbers in new branches and maintain a similar product mix to established operations. The company expects to receive approvals for 1-2 new provinces each year [10][11]. Summary by Sections Share Buybacks - AIA Group has decided to shorten the buyback period to three months to take advantage of low share prices, with the next review of capital position and free surplus generation expected at FY25 results [5]. Market Movements - The report discusses the impact of foreign exchange, interest rates, and equity market movements, noting that the USD weakness primarily affects translation metrics rather than direct business impact. The company has seen a year-to-date decline in bond yields in China and the US, while rates in Thailand have decreased, potentially leading to negative impacts if current levels persist [5][6]. Sales and Growth in Mainland China - AIA reported a -7% year-over-year decline in Value of New Business (VONB) in mainland China, attributed partly to a strong base effect from 1H24. The company expects easier comparisons in 2H25. The sales mix has shifted towards participating products, which have lower margins compared to non-participating products, but traditional products remain unaffected [10][11]. Footprint Expansion - AIA aims to grow agent numbers in new branches to over 1,000 within the first 1.5-2 years and plans to expand to other cities in the provinces of the new branches. The product mix in new branches is similar to established operations, although average ticket sizes are smaller due to lower income levels in these areas [10][11].

Investment Rating - The report does not explicitly provide an investment rating for Shanghai Pudong Development Bank (SPDB) [1]. Core Insights - Revenue and profit growth are expected to accelerate in the remaining quarters of 2025, with ambitious targets set for full-year growth [3]. - The net interest margin (NIM) change in 2025 is anticipated to outperform peers [3]. - Loan growth in 2025 is projected to exceed Rmb 370 billion recorded in 2024 [3]. - Positive growth in mortgage loans is expected for the full year, despite a slower pace compared to previous quarters [3]. - Non-interest income is targeted to achieve positive growth in 2025 [3]. - The company aims to control credit costs while maintaining a stable or higher non-performing loan (NPL) coverage ratio with a decline in the NPL ratio [3]. - A 30% dividend payout ratio is expected to be maintained [3]. Revenue and Profit Growth - The company achieved 1%+ revenue and profit growth in 1Q25 and is confident in accelerating growth for the remaining quarters of 2025 [11]. - The ambitious targets for revenue and profit growth in 2025 are set despite a high base and weak bond market performance [11]. Net Interest Margin (NIM) - NIM saw marginal improvement in 1Q25, with a limited year-over-year decline, outperforming peers [7]. - The NIM is expected to remain stable in 2Q25 and outperform peers throughout 2025 [7]. - Factors contributing to NIM improvement include accelerated loan growth and optimized liability structure [7]. Loans - Loan growth in 2025 is expected to exceed Rmb 370 billion, with a balanced growth pace throughout the year [7]. - New loan growth in 1Q25 was Rmb 250 billion, significantly faster than peers [7]. - The focus will be on five key areas: technology finance, supply chain finance, inclusive finance, cross-border finance, and wealth management [7]. Mortgages - Mortgage loans are expected to achieve positive growth in 2025, particularly in tier 1 and 2 cities [7]. - Both 1Q25 and 2Q25 saw positive mortgage growth, although less significant than in 4Q24 [7]. - The mortgage NPL ratio increased slightly in 1Q25 but remains under control [7]. Non-Interest Income - Non-interest income is targeted for positive growth in 2025, with future growth drivers identified [11]. - Fee income growth was negative in 1Q25 due to a decline in corporate underwriting income, while agency sales and custody income grew [11]. - Positive investment income growth in 1Q25 was attributed to opportunistic bond investment gains and growth in precious metals and FX derivatives trading income [11]. Asset Quality - The company aims to achieve a decline in the NPL ratio while maintaining a stable or higher NPL coverage ratio [11]. - The main asset quality risk lies in retail, with the NPL ratio for developer loans decreasing quarter-over-quarter in 1Q25 [11].

Investment Rating - The investment rating for Sunny Optical is Equal-weight [6] Core Insights - Vehicle-related businesses are identified as the key growth driver, while smartphone-related businesses are focusing on margin improvement [1] - Vehicle lens demand is projected to increase from 317 million units in 2024 to 552 million units by 2030, representing a 10% CAGR [1] - Smart lamp shipments are expected to achieve a 55% CAGR from 2025 to 2030, while AR-HUD shipments are anticipated to grow at a 38% CAGR from 2023 to 2030 [2] - LiDAR shipments are also projected to reach a CAGR of 55% from 2023 to 2030 [2] - The smartphone camera module market size is expected to grow from RMB 240 billion in 2024 to RMB 293 billion in 2028, driven by high-end products [2] - The margin recovery for smartphone business lines is likely to continue due to new product innovations and vertical integration [3] - The company is actively investing in R&D to gain a competitive edge in XR and robotic businesses [4] Summary by Sections Vehicle Lens Market - The global vehicle lens market is expected to grow significantly, with demand projected to rise from 317 million units in 2024 to 552 million units by 2030, indicating a 10% CAGR [1][9] Smart Lamp and AR-HUD - Smart lamp shipments are forecasted to grow at a 55% CAGR from 2025 to 2030, while AR-HUD shipments are expected to achieve a 38% CAGR from 2023 to 2030 [2] Smartphone Camera Module - The smartphone camera module market is projected to expand from RMB 240 billion in 2024 to RMB 293 billion in 2028, supported by growth in high-end products [2] Margin Recovery - The recovery of margins in smartphone business lines is anticipated to continue, driven by innovations and vertical integration [3] R&D Investments - The company is making proactive R&D investments to establish a competitive advantage in XR and robotic sectors [4]

Investment Rating - The report assigns a Neutral rating to China Pacific Insurance (CPIC) with a 12-month price target of HK$23.50 for H-shares and Rmb26.50 for A-shares, indicating a downside of 6.0% and 24.0% respectively [9][13]. Core Insights - Strong sales momentum has been observed in the first quarter of FY25, continuing into the second quarter, with the mix of participating product sales increasing to over 30% by the end of May, compared to approximately 20% in 1Q25 [5]. - CPIC's agency headcount has stabilized year-to-date, with plans to increase recruitment starting in the second half of FY24, focusing on improving agent productivity [5]. - The bancassurance channel has shown strong growth in value of new business (VONB) for FY24, with expectations of similar momentum in FY25, particularly in tier 1-2 cities [5]. - Investment in equity and funds remains stable at around 12% of total investment assets, with a new money yield of approximately 2.5% [12]. Sales Momentum - The sales momentum in 1Q25 has continued into 2Q25, with a notable increase in the sales mix of participating products [5]. - The agency channel aims to promote health and protection products to improve margins and diversify the product mix [5]. - The bancassurance channel strategy focuses on tier 1-2 cities to access mid-to-high-end customers, maintaining key partnerships with banks [5]. Asset and Liability Management - CPIC's current effective duration gap is 3-4 years, with an asset duration of 11.6 years [12]. - The blended guaranteed cost of liability is around 2.8%, expected to be lower than 2.5% when including positive expense and risk margins [12]. Shareholders' Return - CPIC will maintain its annual payout policy and has not proposed a detailed plan for share buybacks, despite receiving authorization from the AGM [12]. - The company emphasizes total payout ratio over more frequent dividend payments, indicating a focus on long-term shareholder returns [12].

Investment Rating - The report assigns a "Sell" rating to New China Life Insurance (NCI) with a 12-month price target of HK$20.50 and Rmb28.50, indicating a downside potential of approximately 47.6% and 49.3% respectively [7][9]. Core Insights - Recent sales momentum has shifted towards participating products, which accounted for over half of new premiums in the agency channel during April and May. The company aims for a 30% participating product mix by FY25 [5][6]. - NCI's investment strategy includes maintaining a stable equity allocation of approximately 16% as of FY24, with plans to increase high dividend investments in FY25. The company is also focusing on long-duration bonds to enhance investment income [6][8]. Sales Momentum and NBV Outlook - Participating product sales have increased since April, moving away from traditional products. The company expects a gradual shift towards participating products over the next 2-3 years [5]. - NCI aims to achieve above-industry NBV growth in FY25, despite the lower margin nature of participating products compared to traditional ones [5][6]. Investment Allocation - NCI's new investments are projected to be around Rmb200-300 billion per year, with a new money yield of 2-3% for fixed income investments. The asset allocation strategy is primarily focused on fixed income (70-80%) and equity (20%) [8]. - The current cost of liability is above 3%, but NCI anticipates a decrease as new policies guarantee lower costs in 2024 and 2025 [8].

15 June 2025 | 1:53PM HKT Potential opportunities on other technology platforms: Referring to technology platform-based collaborations between China pharma / biotech and MNCs (see summary in Exhibit 1), the upfront payment of US$110mn for the announced AZ/CSPC collaboration is consistent with the historical range of US$10mn to below US$200mn, while the total deal size of US$5.3bn was the highest since 2023. With the current collaboration announced to date, we see growing recognition from MNCs for CSPC's tec ...

Investment Rating - The report assigns a "Buy" rating for Laopu Gold (6181.HK) with a target price raised to HKD 1,090, indicating an upside potential of 23.7% from the current price of HKD 881.50 [1]. Core Insights - Laopu Gold's earnings are expected to grow by 15-26% in 2025-27E, driven by strong year-to-date sales performance and rapid store expansion, supported by increasing brand awareness and a rising gold price forecast [1][2]. - The company has successfully launched a new product series, "七子葫芦" (Seven-color enamel gold gourd), which has received positive feedback and is expected to enhance brand equity while allowing for higher pricing [2]. - The upcoming quarter is anticipated to be eventful with several strategic initiatives planned, including new product launches and store optimizations, aimed at reinforcing Laopu's market position against traditional jewelers [2][16]. Financial Performance - Revenue projections for Laopu Gold have been significantly revised upwards, with estimates for 2025 increasing from RMB 19,585 million to RMB 26,310 million, reflecting a robust growth trajectory [4]. - The company's online sales have shown remarkable growth, with a total GMV of RMB 1.6 billion from January to May, representing a 511% year-on-year increase [1][22]. - The EBITDA and EPS forecasts have also been adjusted upwards, with 2025 EPS now estimated at RMB 27.60, up from RMB 22.13 [4]. Market Position and Competitive Advantage - Laopu Gold has demonstrated strong same-store sales growth (SSSG) above triple-digit percentages, outperforming both local and international competitors in the jewelry sector [25][26]. - The company is expanding its total store pipeline beyond the initially guided 6-8 new stores, indicating a proactive approach to market expansion [1][2]. - The successful performance of new product launches and the strategic focus on brand differentiation are expected to sustain growth and expand the total addressable market (TAM) [2][25].

Investment Rating - The investment rating for Laopu Gold is "Buy" with a target price of HK$1,084.0, raised from HK$979.0, indicating an expected return of 14.3% and a total return of 16.6% [7][26]. Core Insights - Laopu Gold has successfully narrowed its product price premium over mass-market gold jewelry, making its high-end products more appealing. The company is expected to sustain triple-digit same-store sales growth (SSSG) into the second half of 2025 if gold prices remain high [1][2]. - The company has reinvented the gold jewelry business model by using fixed pricing per item rather than weight-based pricing, which has led to a significant reduction in its price premium from approximately 20% to around 5% since mid-April 2025 [2][3]. - Laopu Gold is changing consumer perceptions of gold jewelry from a commodity to a storytelling artwork, enhancing its competitive landscape and allowing brands to focus on product development rather than price competition [3][4]. - The brand's premium image, characterized by customer experience and unique craftsmanship, is not easily replicable, reducing concerns about competition from copycat products [4][5]. Financial Summary - The net profit for Laopu Gold is projected to grow significantly, with estimates of Rmb 4,727 million for 2025, Rmb 6,459 million for 2026, and Rmb 8,016 million for 2027, reflecting a growth rate of 220.9% in 2025 [6][19]. - The company expects to increase its prices by 9-10% in the second half of 2025, which could widen its price premium to 10-15% if gold prices remain stable [2][5]. - Laopu Gold's revenue is projected to reach Rmb 23,656 million in 2025, with a year-on-year growth rate of 178.1% [18][19]. Market Position - Laopu Gold is ranked as the number one gold jewelry brand in China in terms of single-store sales for 2022 and 2023, with a market share of 31% in the gold jewelry segment as of 2023 [25][26]. - The company has a unique niche in "heritage gold," combining modern designs with traditional Chinese craftsmanship, which has contributed to its strong market position [25][26]. Valuation - The target price of HK$1,084 is based on a price-to-earnings (P/E) ratio of 36x for 2025E, reflecting a premium valuation compared to global luxury peers due to its rapid growth outlook and strong product competitiveness [27].

Investment Rating - The report assigns a "Buy" rating to Hengrui Medicine with a 12-month price target of Rmb55.90, indicating an upside potential of 3.7% from the current price of Rmb53.89 [13][15]. Core Insights - Hengrui Medicine is positioned as a second-tier player in the GLP-1 space, with a comprehensive product offering that includes both oral and injectable formulations, as well as single and dual agonists. The company is expected to launch its innovative drug HRS9531 in 2026 after filing for NDA by the end of 2025 [3][13]. - The oral peptide HRS9531 has shown promising preliminary efficacy, with a placebo-adjusted mean weight loss of -3.5% at Day 29, comparable to orforglipron's -3%. However, it is less effective than Hengrui's injectable HRS-7535, which achieved -5.5% weight loss at week 4 [2][3]. - The injectable form of HRS9531 demonstrated durable weight loss, achieving a placebo-adjusted weight loss of -16.7% at week 24 and maintaining weight stability from week 32 to week 52, with changes ranging from -0.76% to 0.01% [3]. Summary by Sections Product Efficacy - The oral form of HRS9531 showed comparable efficacy to orforglipron, with a weight loss of -3.5% at Day 29, while the injectable form achieved a weight loss of -9.3% at week 4 [2][7]. - The injectable HRS9531 has completed patient enrollment for phase 3 clinical trials and is expected to file for NDA by the end of 2025 [3]. Market Position - Hengrui's competitive advantage lies in its diverse product portfolio and commercial capabilities in metabolic diseases, which could create synergies in the market [3][13]. - The company is projected to see revenue growth, with estimates of Rmb30.37 billion in 2025 and Rmb37.09 billion in 2027 [15].

Investment Rating - The investment rating for Haidilao International Holding Ltd is Overweight, with a price target of HK$20.00, indicating a potential upside of 28% from the current price of HK$15.58 [4]. Core Insights - The report highlights that Haidilao is on track to meet its 2025 target for gross store openings, with an expected acceleration in the second half of 2025. The company aims for a gross opening of more than a mid-single-digit percentage of its existing network [6]. - The gross profit margin (GPM) for 2025 is projected to be lower than in 2024 due to rising raw material costs and enhanced customer services, although lower depreciation expenses may provide some mitigation [6][2]. - The report notes that the staff cost ratio is expected to remain stable year-on-year in 2025, while marketing efforts are being expanded to include regional and store-level initiatives [2]. Financial Metrics - For the fiscal year ending December 2025, the estimated net revenue is projected to be RMB 45,930 million, with an EBITDA of RMB 9,002 million and a net income of RMB 5,338 million [4]. - The earnings per share (EPS) for 2025 is estimated at RMB 0.99, with a projected compound annual growth rate (CAGR) of 14% for EPS from 2025 to 2027 [7]. - The report indicates a price-to-earnings (P/E) ratio of 14.5 for 2025, which is considered reasonable given the macroeconomic uncertainties [7]. Market Context - The report mentions that the overall consumption sentiment remains weak, impacting top-line growth, with a year-on-year decline in table turn for Haidilao observed in May 2025 [6]. - The company is also adjusting its store opening strategy for YEAH Qing BBQ, scaling back slightly to ensure quality openings, targeting 100 gross store openings in 2025 [6].